Ofatumumab (Kesimpta), a new anti-CD20 monoclonal antibody, has received approval from Health Canada for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with active disease defined by clinical and imaging features. In clinical trials, active disease was defined as at least one relapse or one Gd-enhancing lesion in the previous year.
Latest News
Slide deck: COVID-19 – Epidemiology in Canada (January 25, 2021)
January 25, 2021Summary of epidemiology, testing and mortality rate; Canada and world statistics.
COVID vaccine guidance for MS patients
January 22, 2021The Canadian Network of MS Clinics has endorsed a COVID vaccination guidance document developed by the U.S. National MS Society (see links below). The advice is based on expert opinion due to a lack of data on the safety and efficacy of the COVID vaccine in the multiple sclerosis population and applies only to the mRNA vaccines (Pfizer, Moderna) currently available.
Multiple sclerosis 2021 – a look ahead
January 13, 2021To start off the new year, NeuroSens asked some MS experts from across Canada what developments in multiple sclerosis research and management we can expect to see. Some issues were necessarily related to COVID-21. But the prognosticators also identified several important questions that may be answered in the months ahead.